MRK
Merck & Co., Inc.
Price Chart
Latest Quote
$127.90
+4.29 (+3.47%)
Current Price
| Previous Close | $123.61 |
| Open | $124.33 |
| Day High | $128.93 |
| Day Low | $124.00 |
| Volume | 5,578,241 |
Stock Information
| Quarterly Dividend / Yield | $3.40 / 2.75% |
| Shares Outstanding | 2.47B |
| Quarterly Dividend Yield | 2.75% |
| Quarterly Dividend | $3.40 |
| Total Debt | $49.12B |
| Cash Equivalents | $5.70B |
| Revenue | $65.77B |
| Net Income | $8.94B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $315.89B |
| P/E Ratio | 36.03 |
| EPS (TTM) | $3.55 |
| Exchange | NYQ |
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $127.50 | 13,469,100 |
| 2026-07-16 | $127.63 | 13,038,800 |
| 2026-07-15 | $123.61 | 9,053,800 |
| 2026-07-14 | $120.78 | 9,932,900 |
| 2026-07-13 | $124.03 | 5,225,800 |
| 2026-07-10 | $123.54 | 8,388,400 |
| 2026-07-09 | $125.07 | 6,975,500 |
| 2026-07-08 | $125.99 | 7,910,200 |
| 2026-07-07 | $128.86 | 10,174,300 |
| 2026-07-06 | $126.78 | 9,499,300 |
| 2026-07-02 | $129.56 | 7,832,200 |
| 2026-07-01 | $125.37 | 10,761,500 |
| 2026-06-30 | $128.50 | 11,837,200 |
| 2026-06-29 | $129.38 | 9,584,600 |
| 2026-06-26 | $128.66 | 18,891,500 |
| 2026-06-25 | $125.45 | 14,043,800 |
| 2026-06-24 | $120.60 | 10,478,100 |
| 2026-06-23 | $119.60 | 10,469,300 |
| 2026-06-22 | $115.48 | 10,521,200 |
| 2026-06-18 | $113.87 | 29,521,600 |
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
đ° Latest News
The Real Question Buried Inside Merck Stock's Premium Price
Trefis âĸ 2026-07-17T21:51:03Z
Merck Reportedly Goes To Bat In Takeover Battle. But Genomics Stock Reverses.
Investor's Business Daily âĸ 2026-07-17T20:12:18Z
Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move.
Investor's Business Daily âĸ 2026-07-17T16:54:54Z
MRK Stock Jumps on FDA Nod for Cholesterol-Lowering Pill
Zacks âĸ 2026-07-17T16:50:00Z
The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?
24/7 Wall St. âĸ 2026-07-17T15:05:33Z
MRNA Advances Cancer Pipeline With New Immunotherapy Study
Zacks âĸ 2026-07-17T14:59:00Z
New Cholesterol Pill, Earnings Growth Boost Merck Shares
FX Empire âĸ 2026-07-17T12:40:34Z
MSD wins FDA approval for cholesterol pill to help plug Keytruda void
Pharmaceutical Technology âĸ 2026-07-17T10:31:24Z
GSK shelves cough drug acquired in $2B deal
BioPharma Dive âĸ 2026-07-17T09:21:40Z
Why Is PSNL Stock Up 5% After-Hours?
Stocktwits âĸ 2026-07-16T23:27:35Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $16,382,000,000 | $15,193,000,000 | $16,126,000,000 | $17,411,000,000 |
| Cost Of Revenue | $16,382,000,000 | $15,193,000,000 | $16,126,000,000 | $17,411,000,000 |
| Total Revenue | $65,011,000,000 | $64,168,000,000 | $60,115,000,000 | $59,283,000,000 |
| Operating Revenue | $65,011,000,000 | $64,168,000,000 | $60,115,000,000 | $59,283,000,000 |
| Expenses | ||||
| Interest Expense | $1,357,000,000 | $1,271,000,000 | $1,146,000,000 | $962,000,000 |
| Total Expenses | $42,904,000,000 | $43,947,000,000 | $57,161,000,000 | $41,001,000,000 |
| Other Income Expense | $-26,000,000 | $571,000,000 | $-284,000,000 | $-1,033,000,000 |
| Other Non Operating Income Expenses | $818,000,000 | $1,093,000,000 | $345,000,000 | $960,000,000 |
| Net Non Operating Interest Income Expense | $-1,014,000,000 | $-856,000,000 | $-781,000,000 | $-805,000,000 |
| Interest Expense Non Operating | $1,357,000,000 | $1,271,000,000 | $1,146,000,000 | $962,000,000 |
| Operating Expense | $26,522,000,000 | $28,754,000,000 | $41,035,000,000 | $23,590,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $18,254,000,000 | $17,117,000,000 | $365,000,000 | $14,519,000,000 |
| Net Interest Income | $-1,014,000,000 | $-856,000,000 | $-781,000,000 | $-805,000,000 |
| Interest Income | $343,000,000 | $415,000,000 | $365,000,000 | $157,000,000 |
| Normalized Income | $18,985,664,309 | $17,565,606,842 | $861,910,000 | $16,278,819,000 |
| Net Income From Continuing And Discontinued Operation | $18,254,000,000 | $17,117,000,000 | $365,000,000 | $14,519,000,000 |
| Net Income Common Stockholders | $18,254,000,000 | $17,117,000,000 | $365,000,000 | $14,519,000,000 |
| Net Income | $18,254,000,000 | $17,117,000,000 | $365,000,000 | $14,519,000,000 |
| Net Income Including Noncontrolling Interests | $18,263,000,000 | $17,133,000,000 | $377,000,000 | $14,526,000,000 |
| Net Income Continuous Operations | $18,263,000,000 | $17,133,000,000 | $377,000,000 | $14,526,000,000 |
| Pretax Income | $21,067,000,000 | $19,936,000,000 | $1,889,000,000 | $16,444,000,000 |
| Special Income Charges | $-889,000,000 | $-309,000,000 | $-599,000,000 | $-337,000,000 |
| Interest Income Non Operating | $343,000,000 | $415,000,000 | $365,000,000 | $157,000,000 |
| Operating Income | $22,107,000,000 | $20,221,000,000 | $2,954,000,000 | $18,282,000,000 |
| Gross Profit | $48,629,000,000 | $48,975,000,000 | $43,989,000,000 | $41,872,000,000 |
| Net Income Discontinuous Operations | - | - | $0 | $0 |
| Per Share | ||||
| Diluted EPS | $7.28 | $6.74 | $0.14 | $5.71 |
| Basic EPS | $7.38 | $6.77 | $0.14 | $5.73 |
| Other | ||||
| Tax Effect Of Unusual Items | $-112,335,691 | $-73,393,158 | $-132,090,000 | $-233,181,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $29,106,000,000 | $26,228,000,000 | $7,536,000,000 | $23,308,000,000 |
| Total Unusual Items | $-844,000,000 | $-522,000,000 | $-629,000,000 | $-1,993,000,000 |
| Total Unusual Items Excluding Goodwill | $-844,000,000 | $-522,000,000 | $-629,000,000 | $-1,993,000,000 |
| Reconciled Depreciation | $5,838,000,000 | $4,499,000,000 | $3,872,000,000 | $3,909,000,000 |
| EBITDA (Bullshit earnings) | $28,262,000,000 | $25,706,000,000 | $6,907,000,000 | $21,315,000,000 |
| EBIT | $22,424,000,000 | $21,207,000,000 | $3,035,000,000 | $17,406,000,000 |
| Diluted Average Shares | $2,507,000,000 | $2,541,000,000 | $2,607,142,857 | $2,542,000,000 |
| Basic Average Shares | $2,474,626,766 | $2,527,637,335 | $2,607,142,857 | $2,532,000,000 |
| Diluted NI Availto Com Stockholders | $18,254,000,000 | $17,117,000,000 | $365,000,000 | $14,519,000,000 |
| Minority Interests | $-9,000,000 | $-16,000,000 | $-12,000,000 | $-7,000,000 |
| Tax Provision | $2,804,000,000 | $2,803,000,000 | $1,512,000,000 | $1,918,000,000 |
| Restructuring And Mergern Acquisition | $889,000,000 | $309,000,000 | $599,000,000 | $337,000,000 |
| Gain On Sale Of Security | $45,000,000 | $-213,000,000 | $-30,000,000 | $-1,656,000,000 |
| Research And Development | $15,789,000,000 | $17,938,000,000 | $30,531,000,000 | $13,548,000,000 |
| Selling General And Administration | $10,733,000,000 | $10,816,000,000 | $10,504,000,000 | $10,042,000,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $4,346,000,000 | $8,275,000,000 | $-1,627,000,000 | $4,518,000,000 |
| Total Assets | $136,866,000,000 | $117,106,000,000 | $106,675,000,000 | $109,160,000,000 |
| Total Non Current Assets | $93,350,000,000 | $78,324,000,000 | $74,507,000,000 | $73,438,000,000 |
| Other Non Current Assets | $18,818,000,000 | $16,044,000,000 | $11,996,000,000 | $9,528,000,000 |
| Investmentin Financial Assets | $956,000,000 | $463,000,000 | $252,000,000 | - |
| Goodwill And Other Intangible Assets | $48,260,000,000 | $38,038,000,000 | $39,208,000,000 | $41,473,000,000 |
| Other Intangible Assets | $26,681,000,000 | $16,370,000,000 | $18,011,000,000 | $20,269,000,000 |
| Current Assets | $43,516,000,000 | $38,782,000,000 | $32,168,000,000 | $35,722,000,000 |
| Other Current Assets | $10,518,000,000 | $8,706,000,000 | $8,368,000,000 | $7,169,000,000 |
| Inventory | $6,658,000,000 | $6,109,000,000 | $6,358,000,000 | $5,911,000,000 |
| Receivables | $11,775,000,000 | $10,278,000,000 | $10,349,000,000 | $9,450,000,000 |
| Accounts Receivable | $11,775,000,000 | $10,278,000,000 | $10,349,000,000 | $9,450,000,000 |
| Allowance For Doubtful Accounts Receivable | $-97,000,000 | $-89,000,000 | $-88,000,000 | $-72,000,000 |
| Gross Accounts Receivable | $11,872,000,000 | $10,367,000,000 | $10,437,000,000 | $9,522,000,000 |
| Cash Cash Equivalents And Short Term Investments | $14,565,000,000 | $13,689,000,000 | $7,093,000,000 | $13,192,000,000 |
| Cash And Cash Equivalents | $14,565,000,000 | $13,242,000,000 | $6,841,000,000 | $12,694,000,000 |
| Assets Held For Sale Current | - | - | - | - |
| Debt | ||||
| Net Debt | $34,774,000,000 | $23,869,000,000 | $28,214,000,000 | $17,997,000,000 |
| Total Debt | $49,339,000,000 | $37,111,000,000 | $35,055,000,000 | $30,691,000,000 |
| Long Term Debt And Capital Lease Obligation | $46,750,000,000 | $34,462,000,000 | $33,683,000,000 | $28,745,000,000 |
| Long Term Debt | $46,750,000,000 | $34,462,000,000 | $33,683,000,000 | $28,745,000,000 |
| Current Debt And Capital Lease Obligation | $2,589,000,000 | $2,649,000,000 | $1,372,000,000 | $1,946,000,000 |
| Current Debt | $2,589,000,000 | $2,649,000,000 | $1,372,000,000 | $1,946,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $84,204,000,000 | $70,734,000,000 | $69,040,000,000 | $63,102,000,000 |
| Total Non Current Liabilities Net Minority Interest | $55,877,000,000 | $42,314,000,000 | $43,346,000,000 | $38,863,000,000 |
| Other Non Current Liabilities | $7,688,000,000 | $6,465,000,000 | $8,792,000,000 | $8,323,000,000 |
| Non Current Deferred Liabilities | $1,439,000,000 | $1,387,000,000 | $871,000,000 | $1,795,000,000 |
| Non Current Deferred Taxes Liabilities | $1,439,000,000 | $1,387,000,000 | $871,000,000 | $1,795,000,000 |
| Current Liabilities | $28,327,000,000 | $28,420,000,000 | $25,694,000,000 | $24,239,000,000 |
| Payables And Accrued Expenses | $25,738,000,000 | $25,771,000,000 | $24,322,000,000 | $22,293,000,000 |
| Payables | $11,270,000,000 | $10,077,000,000 | $8,556,000,000 | $8,134,000,000 |
| Dividends Payable | $2,140,000,000 | $2,084,000,000 | $1,985,000,000 | $1,884,000,000 |
| Total Tax Payable | $4,726,000,000 | $3,914,000,000 | $2,649,000,000 | $1,986,000,000 |
| Income Tax Payable | $4,726,000,000 | $3,914,000,000 | $2,649,000,000 | $1,986,000,000 |
| Accounts Payable | $4,404,000,000 | $4,079,000,000 | $3,922,000,000 | $4,264,000,000 |
| Liabilities Heldfor Sale Non Current | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $52,606,000,000 | $46,313,000,000 | $37,581,000,000 | $45,991,000,000 |
| Total Equity Gross Minority Interest | $52,662,000,000 | $46,372,000,000 | $37,635,000,000 | $46,058,000,000 |
| Stockholders Equity | $52,606,000,000 | $46,313,000,000 | $37,581,000,000 | $45,991,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-4,287,000,000 | $-4,945,000,000 | $-5,161,000,000 | $-4,768,000,000 |
| Other Equity Adjustments | $-4,287,000,000 | $-4,945,000,000 | $-5,161,000,000 | $-4,768,000,000 |
| Retained Earnings | $73,075,000,000 | $63,069,000,000 | $53,895,000,000 | $61,081,000,000 |
| Other | ||||
| Treasury Shares Number | $1,102,476,756 | $1,049,466,187 | $1,045,470,249 | $1,039,269,638 |
| Ordinary Shares Number | $2,474,626,766 | $2,527,637,335 | $2,531,633,273 | $2,537,833,884 |
| Share Issued | $3,577,103,522 | $3,577,103,522 | $3,577,103,522 | $3,577,103,522 |
| Tangible Book Value | $4,346,000,000 | $8,275,000,000 | $-1,627,000,000 | $4,518,000,000 |
| Invested Capital | $101,945,000,000 | $83,424,000,000 | $72,636,000,000 | $76,682,000,000 |
| Working Capital | $15,189,000,000 | $10,362,000,000 | $6,474,000,000 | $11,483,000,000 |
| Total Capitalization | $99,356,000,000 | $80,775,000,000 | $71,264,000,000 | $74,736,000,000 |
| Minority Interest | $56,000,000 | $59,000,000 | $54,000,000 | $67,000,000 |
| Treasury Stock | $62,999,000,000 | $58,303,000,000 | $57,450,000,000 | $56,489,000,000 |
| Additional Paid In Capital | $45,029,000,000 | $44,704,000,000 | $44,509,000,000 | $44,379,000,000 |
| Capital Stock | $1,788,000,000 | $1,788,000,000 | $1,788,000,000 | $1,788,000,000 |
| Common Stock | $1,788,000,000 | $1,788,000,000 | $1,788,000,000 | $1,788,000,000 |
| Current Accrued Expenses | $14,468,000,000 | $15,694,000,000 | $15,766,000,000 | $14,159,000,000 |
| Investments And Advances | $956,000,000 | $463,000,000 | $252,000,000 | $1,015,000,000 |
| Available For Sale Securities | $956,000,000 | $463,000,000 | $252,000,000 | - |
| Goodwill | $21,579,000,000 | $21,668,000,000 | $21,197,000,000 | $21,204,000,000 |
| Net PPE | $25,316,000,000 | $23,779,000,000 | $23,051,000,000 | $21,422,000,000 |
| Accumulated Depreciation | $-21,914,000,000 | $-19,155,000,000 | $-18,266,000,000 | $-17,985,000,000 |
| Gross PPE | $47,230,000,000 | $42,934,000,000 | $41,317,000,000 | $39,407,000,000 |
| Construction In Progress | $9,166,000,000 | $7,984,000,000 | $8,262,000,000 | $9,186,000,000 |
| Machinery Furniture Equipment | $19,760,000,000 | $18,283,000,000 | $17,763,000,000 | $16,760,000,000 |
| Buildings And Improvements | $17,983,000,000 | $16,360,000,000 | $14,966,000,000 | $13,166,000,000 |
| Land And Improvements | $321,000,000 | $307,000,000 | $326,000,000 | $295,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $0 | $447,000,000 | $252,000,000 | $498,000,000 |
| Trading Securities | - | $463,000,000 | $252,000,000 | - |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $12,360,000,000 | $18,096,000,000 | $9,143,000,000 | $14,707,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $16,472,000,000 | $21,468,000,000 | $13,006,000,000 | $19,095,000,000 |
| Cash Flow From Continuing Operating Activities | $16,472,000,000 | $21,468,000,000 | $13,006,000,000 | $19,095,000,000 |
| Operating Gains Losses | $-368,000,000 | $-14,000,000 | $-340,000,000 | $1,419,000,000 |
| Cash From Discontinued Operating Activities | - | - | $0 | $0 |
| Investing Activities | ||||
| Capital Expenditure | $-4,112,000,000 | $-3,372,000,000 | $-3,863,000,000 | $-4,388,000,000 |
| Investing Cash Flow | $-13,741,000,000 | $-7,734,000,000 | $-14,083,000,000 | $-4,960,000,000 |
| Cash Flow From Continuing Investing Activities | $-13,741,000,000 | $-7,734,000,000 | $-14,083,000,000 | $-4,960,000,000 |
| Net Other Investing Changes | $-58,000,000 | $-127,000,000 | $-36,000,000 | $-89,000,000 |
| Capital Expenditure Reported | $-4,112,000,000 | $-3,372,000,000 | $-3,863,000,000 | $-4,388,000,000 |
| Cash From Discontinued Investing Activities | - | - | $0 | $0 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-5,084,000,000 | $-1,306,000,000 | $-1,346,000,000 | $0 |
| Financing Cash Flow | $-1,922,000,000 | $-7,032,000,000 | $-4,810,000,000 | $-9,119,000,000 |
| Cash Flow From Continuing Financing Activities | $-1,922,000,000 | $-7,032,000,000 | $-4,810,000,000 | $-9,119,000,000 |
| Net Other Financing Charges | $-131,000,000 | $-372,000,000 | $-328,000,000 | $-240,000,000 |
| Cash Dividends Paid | $-8,176,000,000 | $-7,840,000,000 | $-7,445,000,000 | $-7,012,000,000 |
| Common Stock Dividend Paid | $-8,176,000,000 | $-7,840,000,000 | $-7,445,000,000 | $-7,012,000,000 |
| Net Common Stock Issuance | $-5,084,000,000 | $-1,306,000,000 | $-1,346,000,000 | $0 |
| Cash From Discontinued Financing Activities | - | - | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $-2,503,000,000 | $-1,290,000,000 | $-1,755,000,000 | $-2,251,000,000 |
| Issuance Of Debt | $13,880,000,000 | $3,599,000,000 | $5,939,000,000 | $0 |
| End Cash Position | $14,690,000,000 | $13,318,000,000 | $6,909,000,000 | $12,773,000,000 |
| Beginning Cash Position | $13,318,000,000 | $6,909,000,000 | $12,773,000,000 | $8,167,000,000 |
| Effect Of Exchange Rate Changes | $563,000,000 | $-293,000,000 | $23,000,000 | $-410,000,000 |
| Changes In Cash | $809,000,000 | $6,702,000,000 | $-5,887,000,000 | $5,016,000,000 |
| Proceeds From Stock Option Exercised | $92,000,000 | $177,000,000 | $125,000,000 | $384,000,000 |
| Common Stock Payments | $-5,084,000,000 | $-1,306,000,000 | $-1,346,000,000 | $0 |
| Net Issuance Payments Of Debt | $11,377,000,000 | $2,309,000,000 | $4,184,000,000 | $-2,251,000,000 |
| Net Long Term Debt Issuance | $11,377,000,000 | $2,309,000,000 | $4,184,000,000 | $-2,251,000,000 |
| Long Term Debt Payments | $-2,503,000,000 | $-1,290,000,000 | $-1,755,000,000 | $-2,251,000,000 |
| Long Term Debt Issuance | $13,880,000,000 | $3,599,000,000 | $5,939,000,000 | $0 |
| Net Investment Purchase And Sale | $471,000,000 | $-142,000,000 | $1,848,000,000 | $-483,000,000 |
| Sale Of Investment | $1,678,000,000 | $377,000,000 | $2,803,000,000 | $721,000,000 |
| Purchase Of Investment | $-1,207,000,000 | $-519,000,000 | $-955,000,000 | $-1,204,000,000 |
| Net Business Purchase And Sale | $-10,042,000,000 | $-4,093,000,000 | $-12,032,000,000 | $0 |
| Purchase Of Business | $-10,042,000,000 | $-4,093,000,000 | $-12,032,000,000 | $0 |
| Change In Working Capital | $-6,976,000,000 | $-3,667,000,000 | $-2,205,000,000 | $-2,782,000,000 |
| Change In Other Working Capital | $-3,307,000,000 | $-1,416,000,000 | $-2,314,000,000 | $-1,473,000,000 |
| Change In Other Current Liabilities | $195,000,000 | $-49,000,000 | $456,000,000 | $-545,000,000 |
| Change In Payables And Accrued Expense | $-1,594,000,000 | $-1,123,000,000 | $1,617,000,000 | $41,000,000 |
| Change In Accrued Expense | $-1,841,000,000 | $-2,328,000,000 | $1,783,000,000 | $-50,000,000 |
| Change In Payable | $247,000,000 | $1,205,000,000 | $-166,000,000 | $91,000,000 |
| Change In Account Payable | $110,000,000 | $182,000,000 | $-380,000,000 | $-289,000,000 |
| Change In Tax Payable | $137,000,000 | $1,023,000,000 | $214,000,000 | $380,000,000 |
| Change In Income Tax Payable | $137,000,000 | $1,023,000,000 | $214,000,000 | $380,000,000 |
| Change In Inventory | $-1,180,000,000 | $-835,000,000 | $-816,000,000 | $-161,000,000 |
| Change In Receivables | $-1,090,000,000 | $-244,000,000 | $-1,148,000,000 | $-644,000,000 |
| Changes In Account Receivables | $-1,090,000,000 | $-244,000,000 | $-1,148,000,000 | $-644,000,000 |
| Other Non Cash Items | $511,000,000 | $3,966,000,000 | $11,764,000,000 | $1,301,000,000 |
| Stock Based Compensation | $820,000,000 | $761,000,000 | $645,000,000 | $541,000,000 |
| Asset Impairment Charge | $55,000,000 | $39,000,000 | $792,000,000 | $1,749,000,000 |
| Deferred Tax | $-1,671,000,000 | $-1,249,000,000 | $-1,899,000,000 | $-1,568,000,000 |
| Deferred Income Tax | $-1,671,000,000 | $-1,249,000,000 | $-1,899,000,000 | $-1,568,000,000 |
| Depreciation Amortization Depletion | $5,838,000,000 | $4,499,000,000 | $3,872,000,000 | $3,909,000,000 |
| Depreciation And Amortization | $5,838,000,000 | $4,499,000,000 | $3,872,000,000 | $3,909,000,000 |
| Amortization Cash Flow | $2,793,000,000 | $2,395,000,000 | $2,044,000,000 | $2,085,000,000 |
| Amortization Of Intangibles | $2,793,000,000 | $2,395,000,000 | $2,044,000,000 | $2,085,000,000 |
| Depreciation | $3,045,000,000 | $2,104,000,000 | $1,828,000,000 | $1,824,000,000 |
| Gain Loss On Investment Securities | $-368,000,000 | $-14,000,000 | $-340,000,000 | $1,419,000,000 |
| Net Income From Continuing Operations | $18,263,000,000 | $17,133,000,000 | $377,000,000 | $14,526,000,000 |
| Net Short Term Debt Issuance | - | - | $0 | $0 |
| Earnings Losses From Equity Investments | - | - | $-340,000,000 | $1,419,000,000 |
| Other Cash Adjustment Outside Changein Cash | - | - | - | $0 |
Fetched: 2026-06-17